1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PHF6-somatic mutations and their role in pathophysiology of MDS and AML
    Meeting Abstract

    Przychodzen, B.; Gu, X. R.; You, D. W.; Hirsch, C. M.; Clemente, M. J.; Viny, A. D.; Levine, R. L.; Haferlach, T.; Maggendorfer, M.; Sekeres, M. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Diverse mechanisms of vemurafenib resistance in BRAF-mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Durham, B.; Chung, Y. R.; Scott, S.; Getta, B.; Kim, E.; Saven, A.; Stone, R. M.; Rai, K. R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Toxicity of maintenance rituximab in older adults with non-Hodgkin lymphoma
    Meeting Abstract

    Matasar, M. J.; Atoria, C. L.; Elkin, E. B.; Nabhan, C.
    Blood (2015)

    Fulltext@MSK | Save
  • Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902
    Meeting Abstract

    Luger, S.; Wang, V. X.; Paietta, E.; Ketterling, R. P.; Rybka, W.; Lazarus, H. M.; Litzow, M. R.; Rowe, J. M.; Larson, R. A.; Appelbaum, F. R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Real-world ponatinib prescribing patterns and outcomes in US patients
    Meeting Abstract

    Mauro, M. J.; McGarry, L. J.; Yang, M.; Lustgarten, S.; Huang, H.
    Blood (2015)

    Fulltext@MSK | Save
  • Enoxaparin dose reduction for thrombocytopenia in patients with cancer: A quality assessment study
    Meeting Abstract

    Miao, Y.; Soff, G. A.; Parameswaran, R.; Wills, J.; Mantha, S.
    Blood (2015)

    Fulltext@MSK | Save
  • Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: A quality improvement initiative
    Meeting Abstract

    Mantha, S.; Miao, Y.; Sarasohn, D.; Kessler, J.; Parameswaran, R.; Stefanik, S.; Brar, G.; Samedy, P.; Wills, J.; Patel, D.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed/refactory B-lineage non-Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, C. H.; Fanale, M. A.; Shah, B. D.; Advani, R. H.; Chen, R.; Kim, S.; Kostic, A.; Liu, T. N.; Peng, J.; Forero-Torres, A.
    Blood (2015)

    Fulltext@MSK | Save
  • A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Richter, J.; Vij, R.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J. L.; Bensinger, W.; Dimopoulos, M. A.; San Miguel, J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save